Specialty trend reached $62.25 PMPM (+11.1%), largely from utilization growth in oncology, immunology, and dermatology; ...
The therapies are incredible, says Will Shrank, M.D. They can “totally transform the lives of those who can benefit.” But ...
Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the ...
With the January 1, 2027 deadline looming, there remains a disconnect between early-stage momentum and execution maturity. On ...
Machine-learning aging clocks built from proteins, metabolites, and imaging estimated organ-specific biological aging, enabling cross-validation of sleep associations across multi-omics layers. A ...
FDA accelerated approval of sonrotoclax targets heavily pretreated R/R mantle cell lymphoma post-BTK inhibitor exposure, expanding options in a disease characterized by frequent relapse and limited ...
Cross-sectional secondary analyses used SF-36 pain interference responses and medical-record diagnoses to operationalize ...
Financial hardship correlated strongly with nonadherence, with 37.3% of nonadherent participants unable to get by financially ...
Levitt said KFF polling suggests patient frustration with prior authorization remains widespread across employer-sponsored ...
After step-up dosing, treatment with bispecific antibodies does not require the use of steroids, Adams noted, so patients are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results